
When Covid struck, Claes Gustafsson faced some life or death choices after 17 years running his Silicon Valley business ATUM. He made an epic pivot that has the company fighting Covid by supplying cellular components to help build antibody tests, drugs and vaccines.
Now thriving, he credits his nimble decision making to several factors, but among them: He’s 100% privately owned and had no pesky investors to second guess his rapid decision making. We discuss the incredible science behind ATUM's work to fight coronavirus (including the latest on getting a vaccine), as well as why Claes is against getting VC funding, and how he's thrived during Covid without it.